# Rapport Therapeutics

**Canonical:** https://apis.io/providers/rapport-therapeutics/  
**Website:** https://www.rapportrx.com/  
**APIs profiled:** 0

Rapport Therapeutics, Inc. (Nasdaq: RAPP) is a clinical-stage biotechnology company headquartered in Boston, Massachusetts with research operations in San Diego, California, founded in 2022 and taken public in a $174 million IPO in June 2024. Rapport develops precision small-molecule medicines for central nervous system disorders using its proprietary RAP technology platform, which pairs human genetics with functional proteomics to identify receptor-associated proteins that confer neuroanatomical specificity — the goal being drugs that act only where the disease circuit lives rather than across the whole brain. Its lead clinical candidate, RAP-219, is a selective negative allosteric modulator of TARP-gamma-8-associated AMPA receptors in development for focal onset seizures, peripheral neuropathic pain and bipolar disorder, behind two discovery-stage nicotinic acetylcholine receptor programs targeting alpha-6 (chronic pain) and alpha-9-alpha-10 (hearing disorders). Rapport is a therapeutics developer, not a software vendor: the RAP platform is an internal discovery capability and the company publishes no developer program, no public API and no machine-readable API contract.

## Kin Score — 10.7 / 100 (minimal)

Scored 2026-09-02 under rubric 0.18.0. Trend: flat (+0.0 from 10.7).

| Facet | Score |
|---|---|
| Discoverability | 57.4 |
| Contract Quality | 0.0 |
| Governance | 0.0 |
| Contract Governance | 0.0 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 4.8 |
| Commercial Clarity | 21.1 |
| Access Clarity | 21.1 |

Regulatory layer — **Health**: 17.5 (matched via tags).

## Agent readiness — 0.0 (human-only)

| Dimension | Value |
|---|---|
| Spec Presence | no |
| Agentic Access | no |
| Reversibility Documented | no |
| MCP Server | no |
| Auth Clarity | no |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | no |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |
| Delegated Identity | no |
| Protected Resource Metadata | no |
| Dynamic Client Registration | no |
| Agentic Commerce | no |

## Access

Unknown — onboarding: unknown, pricing: unknown, trial: no (confidence: low).

## Security (1)

- **Rapport Therapeutics Domain Security** — TLSv1.3 · HSTS · DMARC

## Tags

Company, Biotechnology, Pharmaceuticals, Life Sciences, Healthcare, Neuroscience, Central Nervous System, Drug Discovery, Clinical Trials, Epilepsy

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/rapport-therapeutics/). Scores are computed from the provider's own public artifacts under a published rubric.